| Literature DB >> 7758234 |
P F Plouin1, J Bertherat, G Chatellier, E Billaud, M Azizi, E Grouzmann, J Epelbaum.
Abstract
OBJECTIVE: The observation that phaeochromocytoma possess specific somatostatin binding sites led us to test the hypothesis that octreotide may have antisecretory potential in patients with phaeochromocytoma. We therefore compared the effects of octreotide and placebo on blood pressure and plasma catecholamines and neuropeptide Y. PATIENTS: Ten consecutive patients referred to a tertiary care centre for the diagnosis and treatment of a phaeochromocytoma. DESIGN AND MEASUREMENTS: We performed a crossover comparison of either three 100 micrograms subcutaneous injections of octreotide over one day or 3 injections of octreotide vehicle over another. Blood pressure was measured over 24 hours on each test day using an automatic ambulatory recorder. Blood samples were collected before (at 0800 and 0900 h) and after (at 1000, 1100, 1200, 1300 and 1500 h) placebo or octreotide injection. Plasma catecholamines were assayed by high-performance liquid chromatography and neuropeptide Y was determined using a two-site amplified enzyme immunoassay. All patients then underwent surgery and tumoral somatostatin binding site density was determined by quantitative autoradiography.Entities:
Mesh:
Substances:
Year: 1995 PMID: 7758234 DOI: 10.1111/j.1365-2265.1995.tb01877.x
Source DB: PubMed Journal: Clin Endocrinol (Oxf) ISSN: 0300-0664 Impact factor: 3.478